12 related news articles for

Two new candidates have been identified as crucial factors in maintaining good intestinal health.…  Read more

The immune system wages a constant war against disease in all of us, and now researchers have identified a key immune molecule that could underpin a bowel cancer breakthrough.…  Read more

For clinicians, detecting cancer is a victory in itself, but stopping its spread is crucial to a successful outcome. For Professor Ron Firestein, 2021 brought welcome results in that endeavour, thanks to the discovery that disabling two proteins together robs bowel cancer cells of their ability to express genes necessary for growth and spread.…  Read more

A colon cancer research breakthrough at Hudson Institute has shown that combining two types of drugs targeting gene expression stops cancer proliferation.…  Read more

Six Early Career Researchers have been chosen for the 2021 Hudson Institute Emerging Leaders program.…  Read more

Drugs that are being trialled to treat leukaemia could also be used to fight bowel cancer after a breakthrough by Hudson Institute of Medical Research scientists.…  Read more

Congratulations to Dr Marius Dannappel and Dr Madara Ratnadiwakara who have been awarded The Ron Evans AM Fellowship to progress treatments for bowel cancer.…  Read more

Hudson Institute researchers have identified a target for controlling the development of colon cancer that could lead to novel treatment strategies.…  Read more

Improved treatments for a range of cancers could be possible following a discovery that stomach cancer is mainly driven by a different process than previously believed.…  Read more

Hudson Institute’s Cancer Genetics and Functional Genomics Postdoctoral Scientist, Dr Marius Dannappel, has been awarded a highly sought after Research Fellowship from the DFG (German Research Foundation) that will progress his research aimed at developing treatments for colorectal cancer. The two year early career fellowship will enable Dr Dannappel to continue his research into the…  Read more

Hudson Institute has had outstanding success in the recent National Health and Medical Research Council (NHMRC) Fellowship and Development Grant announcements.…  Read more

Targeted genetic treatment for cancer is a step closer, with a world-first clinical trial set to test the effectiveness of a new class of drugs called BET inhibitors in treating prostate and colorectal cancer. A team of clinicians and researchers at Hudson Institute of Medical Research and Monash University has been awarded a $2 million…  Read more